Azithromycin powder versus erythromycin in the treatment of chlamydial cervicitis in pregnancy

Marcus E. Gunter, Charles Adair, J. M. Ernest, Gayle McEiroy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: Determine if a single one gram dose of azithromycin (Pfizer Labs, New York, NY) has fewer side effects and better compliance rate than a multiple dose regimen of erythromycin in the treatment of chlamydial cervicitis in pregnancy. Study Design: There is an ongoing randomized clinical trial. All women attending their first and 36 week prenatal visit had cervical swabs taken and analyzed with the Gen-Probe PACE 2 (Gen-Probe, Inc., San Diego, CA) DNA probe for Chlamydia trachomatis. AU patients with positive results were asked to participate. Patients were assigned to receive either a one gram oral dose of azithromycin powder or seven days of erythromycin base, 500 mg q.i.d. Patients unable to tolerate original randomization medications due to gastrointestinal side effects were allowed to crossover to the opposite study medication. Test of cure swabs were obtained two weeks after completion of treatment. Patients testing positive for Chlamydia trachomatis at follow-up were considered treatment failures and retreated with the other agent. The incidence of side effects and compliance rates were assessed by patient questionnaire at the two week follow-up visit. Results: Forty-seven women have been randomized. Variable Azithromycin Erythromycin pN = 22 N = 18 Compliance 22 (100%) 8 (44,5%) ≤0.001 Gastrointestinal side effects 3 (14.3%) 11 (61.1%) ≤0.001 Posilive follow-up cultures 0 (0%) 1 (5.3%) NS=x2; data expressed N (%) Twenty-seven percent of patients treated with erythromycin were unable to tolerate the medication due to gastrointestinal side effects and required crossover to azithromycin. No patient in the azithromycin group required crossover. Conclusions: Azithromycin powder is better tolerated and has a higher compliance rate thar erythromycin in the treatment of chtamydial cervicitis in pregnancy.

Original languageEnglish (US)
Number of pages1
JournalInfectious Diseases in Obstetrics and Gynecology
Volume4
Issue number1
StatePublished - Dec 1 1996
Externally publishedYes

Fingerprint

Uterine Cervicitis
Azithromycin
Erythromycin
Powders
Pregnancy
Chlamydia trachomatis
Therapeutics
DNA Probes
Random Allocation
Treatment Failure
Compliance
Randomized Controlled Trials
Incidence

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Obstetrics and Gynecology
  • Infectious Diseases

Cite this

Azithromycin powder versus erythromycin in the treatment of chlamydial cervicitis in pregnancy. / Gunter, Marcus E.; Adair, Charles; Ernest, J. M.; McEiroy, Gayle.

In: Infectious Diseases in Obstetrics and Gynecology, Vol. 4, No. 1, 01.12.1996.

Research output: Contribution to journalArticle

@article{4dc1871dfdee439d98b0052bfbbaccec,
title = "Azithromycin powder versus erythromycin in the treatment of chlamydial cervicitis in pregnancy",
abstract = "Objectives: Determine if a single one gram dose of azithromycin (Pfizer Labs, New York, NY) has fewer side effects and better compliance rate than a multiple dose regimen of erythromycin in the treatment of chlamydial cervicitis in pregnancy. Study Design: There is an ongoing randomized clinical trial. All women attending their first and 36 week prenatal visit had cervical swabs taken and analyzed with the Gen-Probe PACE 2 (Gen-Probe, Inc., San Diego, CA) DNA probe for Chlamydia trachomatis. AU patients with positive results were asked to participate. Patients were assigned to receive either a one gram oral dose of azithromycin powder or seven days of erythromycin base, 500 mg q.i.d. Patients unable to tolerate original randomization medications due to gastrointestinal side effects were allowed to crossover to the opposite study medication. Test of cure swabs were obtained two weeks after completion of treatment. Patients testing positive for Chlamydia trachomatis at follow-up were considered treatment failures and retreated with the other agent. The incidence of side effects and compliance rates were assessed by patient questionnaire at the two week follow-up visit. Results: Forty-seven women have been randomized. Variable Azithromycin Erythromycin pN = 22 N = 18 Compliance 22 (100{\%}) 8 (44,5{\%}) ≤0.001 Gastrointestinal side effects 3 (14.3{\%}) 11 (61.1{\%}) ≤0.001 Posilive follow-up cultures 0 (0{\%}) 1 (5.3{\%}) NS=x2; data expressed N ({\%}) Twenty-seven percent of patients treated with erythromycin were unable to tolerate the medication due to gastrointestinal side effects and required crossover to azithromycin. No patient in the azithromycin group required crossover. Conclusions: Azithromycin powder is better tolerated and has a higher compliance rate thar erythromycin in the treatment of chtamydial cervicitis in pregnancy.",
author = "Gunter, {Marcus E.} and Charles Adair and Ernest, {J. M.} and Gayle McEiroy",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
journal = "Infectious Diseases in Obstetrics and Gynecology",
issn = "1064-7449",
publisher = "Hindawi Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Azithromycin powder versus erythromycin in the treatment of chlamydial cervicitis in pregnancy

AU - Gunter, Marcus E.

AU - Adair, Charles

AU - Ernest, J. M.

AU - McEiroy, Gayle

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Objectives: Determine if a single one gram dose of azithromycin (Pfizer Labs, New York, NY) has fewer side effects and better compliance rate than a multiple dose regimen of erythromycin in the treatment of chlamydial cervicitis in pregnancy. Study Design: There is an ongoing randomized clinical trial. All women attending their first and 36 week prenatal visit had cervical swabs taken and analyzed with the Gen-Probe PACE 2 (Gen-Probe, Inc., San Diego, CA) DNA probe for Chlamydia trachomatis. AU patients with positive results were asked to participate. Patients were assigned to receive either a one gram oral dose of azithromycin powder or seven days of erythromycin base, 500 mg q.i.d. Patients unable to tolerate original randomization medications due to gastrointestinal side effects were allowed to crossover to the opposite study medication. Test of cure swabs were obtained two weeks after completion of treatment. Patients testing positive for Chlamydia trachomatis at follow-up were considered treatment failures and retreated with the other agent. The incidence of side effects and compliance rates were assessed by patient questionnaire at the two week follow-up visit. Results: Forty-seven women have been randomized. Variable Azithromycin Erythromycin pN = 22 N = 18 Compliance 22 (100%) 8 (44,5%) ≤0.001 Gastrointestinal side effects 3 (14.3%) 11 (61.1%) ≤0.001 Posilive follow-up cultures 0 (0%) 1 (5.3%) NS=x2; data expressed N (%) Twenty-seven percent of patients treated with erythromycin were unable to tolerate the medication due to gastrointestinal side effects and required crossover to azithromycin. No patient in the azithromycin group required crossover. Conclusions: Azithromycin powder is better tolerated and has a higher compliance rate thar erythromycin in the treatment of chtamydial cervicitis in pregnancy.

AB - Objectives: Determine if a single one gram dose of azithromycin (Pfizer Labs, New York, NY) has fewer side effects and better compliance rate than a multiple dose regimen of erythromycin in the treatment of chlamydial cervicitis in pregnancy. Study Design: There is an ongoing randomized clinical trial. All women attending their first and 36 week prenatal visit had cervical swabs taken and analyzed with the Gen-Probe PACE 2 (Gen-Probe, Inc., San Diego, CA) DNA probe for Chlamydia trachomatis. AU patients with positive results were asked to participate. Patients were assigned to receive either a one gram oral dose of azithromycin powder or seven days of erythromycin base, 500 mg q.i.d. Patients unable to tolerate original randomization medications due to gastrointestinal side effects were allowed to crossover to the opposite study medication. Test of cure swabs were obtained two weeks after completion of treatment. Patients testing positive for Chlamydia trachomatis at follow-up were considered treatment failures and retreated with the other agent. The incidence of side effects and compliance rates were assessed by patient questionnaire at the two week follow-up visit. Results: Forty-seven women have been randomized. Variable Azithromycin Erythromycin pN = 22 N = 18 Compliance 22 (100%) 8 (44,5%) ≤0.001 Gastrointestinal side effects 3 (14.3%) 11 (61.1%) ≤0.001 Posilive follow-up cultures 0 (0%) 1 (5.3%) NS=x2; data expressed N (%) Twenty-seven percent of patients treated with erythromycin were unable to tolerate the medication due to gastrointestinal side effects and required crossover to azithromycin. No patient in the azithromycin group required crossover. Conclusions: Azithromycin powder is better tolerated and has a higher compliance rate thar erythromycin in the treatment of chtamydial cervicitis in pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=33748129543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748129543&partnerID=8YFLogxK

M3 - Article

VL - 4

JO - Infectious Diseases in Obstetrics and Gynecology

JF - Infectious Diseases in Obstetrics and Gynecology

SN - 1064-7449

IS - 1

ER -